Diagnosis and Evidence-Based Treatment
ADHD diagnosis in adults requires: (1) Symptoms of inattention and/or hyperactivity-impulsivity present since childhood (typically before age 12), even if not diagnosed at the time; (2) Symptoms causing significant impairment in at least two domains (work, academic, social, family); (3) Symptoms not better explained by another condition (anxiety, depression, learning disabilities, sleep disorder, thyroid dysfunction). The diagnostic process involves a clinical interview, behavioral rating scales (the Adult ADHD Self-Report Scale, Conners Adult ADHD Rating Scale), collateral information from a partner, family member, or colleague when possible, and exclusion of medical and psychiatric mimics. Neuropsychological testing (comprehensive cognitive assessment) can help characterize executive function deficits but is not required for diagnosis.
Stimulant medications are the first-line pharmacological treatment and the most extensively evidence-supported intervention in psychiatry. Meta-analyses confirm that stimulants improve ADHD symptoms (inattention, hyperactivity, impulsivity) with effect sizes of 0.9-1.1 — among the largest of any psychiatric medication. Methylphenidate (Ritalin, Concerta) and amphetamine-based medications (Adderall, Vyvanse) work by increasing dopamine and norepinephrine availability in prefrontal synapses — directly addressing the underlying neurotransmitter deficit. Both short-acting (peak effect 3-6 hours) and long-acting (8-12 hours) formulations are available; long-acting medications are preferred for most adults due to smoother effect profiles and lower abuse potential. Approximately 70-80% of adults respond adequately to first-line stimulant treatment.
Non-stimulant medications: atomoxetine (a selective norepinephrine reuptake inhibitor) and viloxazine (also noradrenergic) are non-stimulant alternatives with good evidence for adult ADHD. They take 4-6 weeks to achieve full effect (vs 1-2 hours for stimulants) and are preferred for patients with substance use history, cardiovascular contraindications, or severe anxiety. Bupropion (a dopamine-norepinephrine reuptake inhibitor primarily used as an antidepressant) has ADHD evidence as a second-line option. Guanfacine and clonidine (alpha-2 adrenergic agonists) are used primarily for hyperactivity and impulsivity, particularly in combination with stimulants.
Cognitive behavioral therapy for ADHD: while CBT is not as effective as medication for core ADHD symptoms, it significantly improves outcomes for the functional consequences of ADHD — disorganization, time management, procrastination, emotional dysregulation, low self-esteem, and the anxiety and depression that commonly co-occur. ADHD-specific CBT focuses on: building external organizational systems (calendars, planners, alarms) to compensate for impaired internal time awareness; developing structured routines that reduce reliance on working memory; and addressing the shame and self-blame that accumulate from years of unrecognized ADHD-related functional failures.